BAP1 and Rhabdoid Meningioma: The BAP1 mutation was first described in rhabdoid meningiomas.282 BAP1 null cells rely on the enhancer of zeste homolog 2 (EZH2) for transformation, which is highly sensitive to EZH2 inhibition, thus opening new therapeutic perspectives.283 However, the work to translate molecular knowledge into clinical management is still ongoing.